Immune checkpoint and inflammation as therapeutic targets in pancreatic carcinoma

doi:10.3748/wjg.v22.i33.7440

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 22, Issue 33

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (11425)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-1) series, Tables (1-2) series.

Item

Count

PDF

703

WORD

304

HTML

7406

Figures (1-1)

352

Tables (1-2)

273

Sum=9038

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

1046

Download

1341

Sum=2387

Sep 7, 2016 (publication date) through Jan 3, 2025

Times Cited of This Article

Times Cited (16)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Review

World J Gastroenterol. Sep 7, 2016; 22(33): 7440-7452
Published online Sep 7, 2016. doi: 10.3748/wjg.v22.i33.7440

Table 2 Problems of each combination therapy

Treatment	Disease	Phase	Clinical trial number	Status
Checkpoint inhibitor plus cytotoxic agents
Ipilimumab (anti-CDLA-4)	PC	1	NCT01473940	Ongoing
Gemcitabine	PC	1	NCT01473940	Ongoing
Nivolumab (anti-PD-1)	PC	1	NCT02309177	Ongoing
Nab-PTX ± gemcitabine	PC	1	NCT02309177	Ongoing
Combination with checkpoint inhibitors
Nivolumab (anti-PD-1)	TNBC, GC, PC,	1, 2	NCT01928394	Ongoing
Ipilimumab (anti-CTLA-4)	SLCL. BC, OC	1, 2	NCT01928394	Ongoing
MEDI4736 (anti-PD-1)	Solid tumor	1	NCT02261220	Ongoing
Tremelimumab (anti-CTLA-4)	Solid tumor	1	NCT02261220	Ongoing
Nivolumab (anti-PD-1)	Cervical cancer, BC, CRC, HN, GC, HCC, melanoma, NSCLC	1, 2	NCT01968109	Ongoing
BMS-986016 (anti-LAG-3)	Cervical cancer, BC, CRC, HN, GC, HCC, melanoma, NSCLC	1, 2	NCT01968109	Ongoing
PDR001 (anti-PD-1)	Solid tumors	1, 2	NCT02608268	Ongoing
MBG453 (anti-TIM-3)	Solid tumors	1, 2	NCT02608268	Ongoing
Ipilimumab (anti-CDLA-4)	B7-H3 expressing tumors (melanoma, HN, NSCLC)	1, 2	NCT02381314	Ongoing
MGA271 (anti-B7-H3)	B7-H3 expressing tumors (melanoma, HN, NSCLC)	1, 2	NCT02381314	Ongoing
Pembrolizumab (anti-PD-1)	B7-H3 expressing tumors	1, 2	NCT02475213	Ongoing
MGA271 (anti-B7-H3)	(melanoma, HN, NSCLC)	1, 2	NCT02475213	Ongoing
Checkpoint inhibitor plus T cells stimulate agents
Nivolumab (anti-PD-1)	Solid tumors, B-cell NHL	1, 2	NCT02253992	Ongoing
Urelumab (anti-4-1 BB)	Solid tumors, B-cell NHL	1, 2	NCT02253992	Ongoing
Pembrolizumab (anti-PD-1)	Solid tumors	1	NCT02179918	Ongoing
Urelumab (anti-4-1 BB)	Solid tumors	1	NCT02179918	Ongoing
Tremelimumab (anti-CTLA-4)	Solid tumors	1, 2	NCT02205333	Ongoing
MEDI6469 (anti-OX-40	Solid tumors	1, 2	NCT02205333	Ongoing
MEDI4736 (anti-PD-L1)	Solid tumors	1, 2	NCT02205333	Ongoing
MEDI6469 (anti-OX-40)	Solid tumors	1, 2	NCT02205333	Ongoing
Tremelimumab (anti-CTLA-4)	Melanoma	1	NCT01103635	Ongoing
CP-870,893 (anti-CD40)	Melanoma	1	NCT01103635	Ongoing
Checkpoint inhibitor plus cancer vaccine
Ipilimumab (anti-CTLA-4) + GVAX	PC	2	Ref 58	Terminated
FOLFIRINOX followed by	PC	2	NCT01896869	Ongoing
Ipilimumab (anti-CTLA-4) + GVAX	PC	2	NCT01896869	Ongoing
Nivolumeb (anti-PD-1) + GVAX	PC	2	NCT02243371	Ongoing
Checkpoint inhibitor plus raditaion
Ipilimumab + radiation	Melanoma	1	NCT01557114	Terminated
	Melanoma	2	NCT016899747	Terminated
	NSCLC	2	NCT0221739	Ongoing
	Melanoma	2	NCT01970527	Ongoing

BC: Bladder cancer; CRC: Colorectal cancer; HN: Head and neck cancer; NSCLC: Non-small cell lung cancer; OC: Ovarian cancer; PC: Pancreatic cancer; SCLC: Small cell lung cancer.

Citation: Kimbara S, Kondo S. Immune checkpoint and inflammation as therapeutic targets in pancreatic carcinoma. World J Gastroenterol 2016; 22(33): 7440-7452
URL: https://www.wjgnet.com/1007-9327/full/v22/i33/7440.htm
DOI: https://dx.doi.org/10.3748/wjg.v22.i33.7440